MedWatch

Top picks in English

Research exec on Novo's diabetes pill: "I was convinced it would get me fired"

Lars Fogh Iversen, who was recently put in charge of Novo Nordisk's internal research, has been very involved in the company's work to develop a tablet version of the GLP-1 molecule semaglutide. But when the project began more than ten years ago, it did not look very promising and it would not have happened without teamwork across the organization, he says.

Analysts: Hearing loss drugs will not disrupt the industry - yet

Drugs against hearing loss are moving closer and may eventually become a competitor to the established hearing aid companies. A fully developed drug still has long prospects, however, companies such as GN Hearing and William Demant should keep an eye on the development.

Reapplix starts company in Texas and gears up for US launch of diabetes patch

Danish company Reapplix has presented new, good data for a biological patch that heals diabetic foot ulcers, and the company has therefore established a subsidiary in the US, which will be in charge of launching the product on the US market. At the same time, the company has hired a CFO and has secured more funding from its investors, including Novo Holdings, Seed Capital and Vækstfonden.

Gubra awarded grant to develop smart insulin: "We'll become 3-4 times faster"

Gubra has received a research grant from diabetes organization JDRF in order to develop a new type of insulin with the potential to revolutionize the treatment of type 1 diabetes and make other types of insulin obsolete. According to CSO Keld Fosgerau, the project can be expanded to maximize value before getting a partner on board.